Indian Journal of Surgical Oncology最新文献

{"title":"Evaluation of p16, HPV E6, and EBV LMP1 Expression in Oral Squamous Cell Carcinoma using Immunohistochemistry to Detect Co-viral Infections.","authors":"Rajesha Payaradka, Pushkal Sinduvadi Ramesh, Vinay Kumar Rajendra, Jayaprakash Shetty, Prakash Patil, Mohana Kumar, Praveenkumar Shetty, Veena Shetty","doi":"10.1007/s13193-026-02588-6","DOIUrl":"https://doi.org/10.1007/s13193-026-02588-6","url":null,"abstract":"<p><strong>Purpose: </strong>Oral squamous cell carcinoma (OSCC) is a significant global health burden, with increasing evidence implicating high-risk viral infections such as human papillomavirus (HPV) and Epstein-Barr virus (EBV) in its pathogenesis. Immunohistochemical (IHC) profiling using viral surrogate markers offers valuable diagnostic and prognostic insights. This study aimed to evaluate the expression of p16, HPV E6, and EBV LMP1 (latent membrane protein) in OSCC tissues using IHC and to explore their associations with clinicopathological parameters, risk factors, recurrence, and survival outcomes, with a particular focus on co-viral infections.</p><p><strong>Methods: </strong>A prospective observational study was conducted between April 2021 and March 2024, including 181 histopathologically confirmed OSCC cases. Fresh tumor tissues were subjected to IHC staining for p16, HPV E6, and EBV LMP1. Marker expression was semi-quantitatively scored, and associations with demographic, clinical, and pathological parameters were analyzed statistically.</p><p><strong>Results: </strong>Although not statistically significant, p16 expression was more frequently observed in well-differentiated and early-stage OSCC, and in patients with combined alcohol and tobacco use. HPV E6 positivity was more common in tumors of the tongue and floor of the mouth and tended to be lower in tobacco users. EBV LMP1 expression was significantly associated with non-recurrence (<i>p</i> = 0.040), while trends with advanced stage and lymph node involvement were observed but not statistically significant. Co-infection with HPV and EBV was detected in12.3% (20/162) of cases, with no significant association to recurrence or survival.</p><p><strong>Conclusion: </strong>IHC detection of p16, HPV E6, and EBV LMP1 provides valuable diagnostic and prognostic information in OSCC. EBV LMP1 may be inversely associated with recurrence, highlighting its potential as a biomarker.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13193-026-02588-6.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"875-887"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailoring Rectal Cancer Treatment: Total Neoadjuvant Therapy and the Shift Towards Organ Preservation.","authors":"Jyotiman Nath, Abhinandan Das, Tapashi Das, Yanpothung Yanthan, Jahnabi Das, Kaushik Kataki","doi":"10.1007/s13193-026-02569-9","DOIUrl":"https://doi.org/10.1007/s13193-026-02569-9","url":null,"abstract":"<p><p>Locally advanced rectal cancer (LARC) remains a significant clinical challenge due to the risks of distant metastasis and treatment-related functional morbidity. Although total mesorectal excision (TME) combined with neoadjuvant chemoradiotherapy (CRT) has achieved excellent locoregional control, limitations in systemic disease control and quality-of-life outcomes have driven the evolution of treatment strategies beyond surgery-centred approaches. Total neoadjuvant therapy (TNT) integrates systemic chemotherapy and radiotherapy entirely within the preoperative phase to improve treatment compliance, enhance tumour regression, and provide earlier control of micrometastatic disease. This strategy has enabled selective organ preservation through nonoperative management (NOM) and watch-and-wait (WW) approaches in patients achieving a clinical complete response. Evidence from landmark trials such as RAPIDO, PRODIGE-23, OPRA, STELLAR, and the recently reported NO-CUT study supports the oncologic efficacy of TNT, while underscoring the importance of appropriate patient selection, treatment sequencing, and structured surveillance. Beyond summarising trial outcomes, this review provides a practical, clinician-oriented framework for contemporary rectal cancer management. We emphasise MRI-based risk stratification to guide selection for TNT, discuss evidence-based sequencing when organ preservation is intended, outline standardised criteria for response assessment, and translate available data into a pragmatic surveillance protocol, with attention to real-world feasibility and resource-limited settings. The review also critically appraises emerging technologies, including adaptive and MR-guided radiotherapy, dose-escalation strategies, circulating tumour DNA, and evolving molecular biomarkers, highlighting their potential roles and current limitations. Overall, this review contextualises TNT within modern rectal cancer care, balancing oncologic safety, functional preservation, and practical implementation.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"938-948"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Bi-Directional Chemotherapy with PIPAC and Systemic Chemotherapy in Advanced Epithelial Ovarian Cancer: An Emerging Conversion Strategy for Initially Unresectable Peritoneal Disease.","authors":"Somashekhar Sp, Rohit Kumar C, Esha R Shanbhag, Ajinkya Pawar, Darshan Patil, Kushal Agrawal, Channappa Patil, Sai Vivek Velkuru, Vaishnavi Srinarahari, Susmita Rakshit, Nikhil S Reddy, Pugazhenthi M, Shabnam S Aboobacker, Vijay Ahuja, Ashwin Kr","doi":"10.1007/s13193-026-02589-5","DOIUrl":"https://doi.org/10.1007/s13193-026-02589-5","url":null,"abstract":"<p><strong>Introduction: </strong>A subset of patients with advanced epithelial ovarian cancer remains unresectable despite standard neoadjuvant chemotherapy (NACT). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) may enhance locoregional response when combined with systemic therapy. We evaluated the safety, feasibility and conversion potential of neoadjuvant bidirectional chemotherapy incorporating PIPAC in patients with initially unresectable disease.</p><p><strong>Methods: </strong>This single-center retrospective observational study included 45 patients with FIGO stage IIIC-IVA epithelial ovarian cancer treated between March 2021 and March 2024. All patients received platinum-taxane NACT. Patients deemed unresectable underwent bidirectional chemotherapy consisting of systemic platinum-based chemotherapy combined with PIPAC. The primary outcome was safety & conversion to complete cytoreductive surgery (CRS) with HIPEC. Secondary outcomes included response rates, perioperative morbidity, and short-term surgical outcomes.</p><p><strong>Results: </strong>Mean age was 54.5 years and median baseline PCI was 21. Following bidirectional therapy, 28 patients (62.2%) achieved sufficient response for conversion CRS with HIPEC. Favourable histological response (PRGS1) was observed in 44.4%, and 53.4% demonstrated good radiological response. Median standardized KELIM was higher in the conversion group (1.10 vs. 0.98). Minor morbidity during therapy occurred in 23.6% and major morbidity in 11.1%, with no 30-day mortality. Among patients undergoing CRS and HIPEC, CC-0 resection was achieved in 82.1%,major postoperative morbidity was 25.4%, and 90-day mortality was 3.5%.</p><p><strong>Conclusion: </strong>Neoadjuvant bidirectional chemotherapy with PIPAC and systemic chemotherapy appears safe, feasible and facilitates surgical conversion in selected patients with advanced ovarian cancer. Prospective studies are warranted to validate long-term survival benefit.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13193-026-02589-5.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"866-874"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Young-Onset Rectal Cancer is Overlooked: Outcome Analysis from a Tertiary Cancer Centre in North India.","authors":"Bhawani Pathak, Sunil Kumar, Svs Deo, Bittu Bhatkal, Sandeep Bhoriwal, Ashutosh Mishra, Amitabha Mandal, Jyoutishman Saikia, Naveen Gupta, Babul Bansal, Akash Jha, Pritee Patil, Karun Kamboj, Seema Mishra, Saurabh Vig, Rajni Yadav, Sanjay Meena, Abhinav Singal, Jyoti Sharma","doi":"10.1007/s13193-026-02594-8","DOIUrl":"https://doi.org/10.1007/s13193-026-02594-8","url":null,"abstract":"<p><strong>Background: </strong>Young-onset rectal cancer (YRC) is increasing worldwide, particularly in low- and middle-income countries (LMICs), where delayed diagnosis and limited access to multimodal treatment adversely affect survival. This study is undertaken to understand the clinical profile of YRC patients at a tertiary cancer centre in North India.</p><p><strong>Methods: </strong>We retrospectively reviewed all patients aged ≤ 40 years with histologically confirmed rectal adenocarcinoma treated between March 2019 and March 2024. Demographic, clinical, histopathological, treatment, and outcome data were collected. Overall survival (OS) was estimated using the Kaplan-Meier method. The study adhered to the STROBE reporting guidelines.</p><p><strong>Results: </strong>Among 151 patients (mean age 29.8 years; 63.6% male), the most common presentation was bleeding per rectum (72.8%), with a mean symptom duration of 7.2 months. Advanced-stage presentation was common, comprising stage III (42.4%) and stage IV disease (29.8%). Adenocarcinoma (64.2%) was the predominant histology, while mucinous (20.5%) and signet-ring cell (15.2%) variants were also frequent. A total of 67 patients (44.4%) were eligible for curative-intent treatment, of whom 47 (31.1% of the overall cohort; 70.1% of eligible patients) completed curative multimodal therapy. Among the remainder, 20 (13.2%) initiated but did not complete curative treatment, 24 (15.9%) received palliative systemic therapy, and 60 (39.7%) were managed with best supportive care alone. At a median follow-up of 12 months, the 1-year OS was 76.2% (95% CI 67.5-86.2). Inferior survival was observed in patients aged ≤ 20 years, those with non-low rectal tumors, and those with locally advanced disease.</p><p><strong>Conclusion: </strong>Most YRC patients presented with advanced disease and limited access to complete multimodal care. Improving early recognition, ensuring timely referral, and expanding equitable access to standard oncologic therapy are essential to improve outcomes in resource-limited settings.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"908-916"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splenic Artery Embolization for Refractory Ascites Following Hepatectomy for Hepatocellular Carcinoma.","authors":"Abdeali Saif Arif Kaderi, Shraddha Patkar, Nitin S Shetty, Kunal B Gala, Suyash Kulkarni, Mahesh Goel","doi":"10.1007/s13193-026-02533-7","DOIUrl":"https://doi.org/10.1007/s13193-026-02533-7","url":null,"abstract":"<p><p>Surgery (Resection/Liver transplant) remains the only curative modality for the treatment of hepatocellular carcinoma (HCC). Post hepatectomy liver failure is the Achilles heel of liver surgery. Management of refractory ascites (RA), following a major resection especially in cirrhotic patients presents a formidable clinical challenge as it is often resistant to conventional treatment modalities. A 72-year gentleman diagnosed with hepatocellular carcinoma in the right lobe of liver with future liver remanent of 45% underwent a right hepatectomy. Postoperatively, despite conservative management with diuretics and albumin he had significantly high drain output. On the 10th day, he underwent proximal splenic artery embolization following which there was a progressive reduction in ascites and drain output. He was discharged in stable condition on the 15th day. Histopathology confirmed moderately differentiated HCC with adjacent steatohepatitis. The patient wass stable and disease free at the 3-month follow-up. Splenic artery embolization offers a safe and minimally invasive technique for management of RA post hepatectomy. Further studies are needed to conclusively establish the safety and utility of this procedure.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"728-733"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Factors for Central Neck Metastasis in cT1N0M0 Papillary Thyroid Cancer Patients Undergoing Transoral Endoscopic Thyroidectomy (TOETVA): A Propensity Score Matched Study.","authors":"Hau Xuan Nguyen, Nhat Tan Nguyen, Hien Xuan Nguyen, Quang Van Le","doi":"10.1007/s13193-026-02575-x","DOIUrl":"https://doi.org/10.1007/s13193-026-02575-x","url":null,"abstract":"<p><strong>Objective: </strong>Selecting patients with cT1N0M0 papillary thyroid carcinoma (PTC) for prophylactic central neck dissection (pCND) remains a challenge. This study aimed to identify predictive factors for occult central lymph node metastasis (oCLNM) in patients undergoing transoral endoscopic thyroidectomy vestibular approach (TOETVA).</p><p><strong>Methods: </strong>This cross-sectional, propensity score-matched study included 80 patients with cT1N0M0 PTC who underwent TOETVA with pCND at Hanoi Medical University Hospital between March 2023 and March 2024. Patients were divided into two matched groups (<i>n</i> = 40 each) based on the presence or absence of oCLNM on final pathology. Baseline characteristics were comparable (<i>p</i> > 0.05).</p><p><strong>Results: </strong>The metastatic group had a significantly higher median number of harvested lymph nodes than the non-metastatic group (5.5 vs. 4.0; <i>p</i> = 0.018). No significant associations were found for tumor size, multifocality, or microscopic extrathyroidal extension (mETE). All five cases of bilobar tumors were observed in the metastatic group. Surgical outcomes, including operative time, blood loss, and hospital stay, were similar between groups.</p><p><strong>Conclusion: </strong>The number of harvested lymph nodes is associated with the detection of oCLNM, while the presence of a bilobar tumor may also be a predictive factor. However, reliably predicting oCLNM preoperatively remains difficult. Larger studies are needed to develop more accurate predictive models for selecting patients for pCND.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"835-840"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discussion of Methodological Limitation in Laparoscopic Versus Radical Nephrectomy Studies.","authors":"Pinky Kumari, Amisha Kumari, Aashi Kumari, Divia Kumari","doi":"10.1007/s13193-026-02543-5","DOIUrl":"https://doi.org/10.1007/s13193-026-02543-5","url":null,"abstract":"","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"719-720"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience in Early Treatment of Congenital Giant Melanocytic Nevus by Tissur Expansion - A Study of 68 Cases.","authors":"Zhang Jiaqi, Chen Cheng, Ge Jun, Chen Chen, Zhang Jinming, Liang Weiqiang","doi":"10.1007/s13193-026-02546-2","DOIUrl":"https://doi.org/10.1007/s13193-026-02546-2","url":null,"abstract":"<p><strong>Background: </strong>Congenital giant melanocytic nevus (GCMN) is a rare congenital lesion associated with potential risks of malignant transformation and neurocutaneous melanosis, which severely impacts patients' appearance and psychological health. Early intervention is crucial, and skin tissue expansion has been recognized as a primary surgical approach. This study aims to explore the feasibility and clinical efficacy of early treatment of GCMN using skin tissue expansion.</p><p><strong>Methods: </strong>A retrospective study was conducted on 68 patients with GCMN who underwent skin tissue expansion treatment in the Department of Plastic Surgery, Sun Yat-sen Memorial Hospital, from October 2013 to December 2022. A total of 214 kidney-shaped expanders were implanted, and the surgical approaches included single-stage expansion and repeated expansion. Complication rates were calculated on both a per-patient and per-expander basis, with comparative analyses performed across different age groups and between internal and external expander ports. Long-term outcomes, including growth and development, symmetry, and functional status, were evaluated using objective criteria.</p><p><strong>Results: </strong>Among the 68 patients, 32 (47.06%) had nevi located on the head and face, 24 (35.29%) on the trunk, 7 (10.29%) on the upper limbs, and 5 (7.35%) on the lower limbs, with all patients presenting multiple satellite lesions. A total of 214 expanders were implanted, with 22 patients receiving 1 expander, 16 receiving 2, 11 receiving 3, 4 receiving 4, 6 receiving 5, and 9 receiving more than 5. Of these expanders, 42 were internally placed and 172 were externally placed. All patients had postoperative drainage tubes. The average hospital stay was 15.13 days (range: 5-107 days), and the average expander removal time was 83.58 days (range: 13-218 days). The follow-up period ranged from 5 to 112 months (mean: 43.53 months). The per-patient complication rate was 69.12% (47/68), and the per-expander complication rate was 43.93% (94/214). No significant differences in complication rates were observed among different age groups (P > 0.05) or between internal and external ports (P > 0.05). Long-term follow-up revealed no growth retardation, trunk asymmetry, scoliosis, or limb developmental disorders; all patients maintained normal limb function and were satisfied with the cosmetic outcomes of the second-stage flap transfer.</p><p><strong>Conclusion: </strong>Skin tissue expansion is a safe and ideal surgical method for the early treatment of congenital giant melanocytic nevus, as it effectively improves patients' appearance, ensures satisfactory long-term functional and cosmetic outcomes, and does not increase the risk of complications or adversely affect growth and development.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"787-793"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Metronomic Oral Capecitabine, Methotrexate and Cyclophosphamide in Locally Advanced Operable Oral Cavity Squamous Cell Carcinoma - A Phase II Study.","authors":"Swarnava Chanda, Pradeep Subramani, Balasubramanian A, Sudhakar G, Prasanth Penumadu, Aman Prakash, Prasanth Ganesan","doi":"10.1007/s13193-026-02596-6","DOIUrl":"https://doi.org/10.1007/s13193-026-02596-6","url":null,"abstract":"<p><strong>Background: </strong>Squamous cell carcinoma (SCC) of the oral cavity mostly presents with advanced disease. Though standard of care is surgery followed by radiation, there is a long wait time in many Indian centres during which some patients progress. We devised a simple, relatively non-toxic oral metronomic chemotherapy (OMCT) regimen aimed at preventing disease progression during the waiting period.</p><p><strong>Methods: </strong>Patients with stage III and IV oral cavity SCC were prospectively included in the trial as per inclusion criteria. They received at least 1 cycle of OMCT unless progression of disease before completion. A maximum of 2 cycles were given, and patients with either stable disease or partial response were operated any time after completion of 1 cycle of OMCT. Progressive disease was managed either with surgery, concurrent chemoradiation or IV NACT f/b surgery or concurrent chemoradiation. Details of sociodemographic, diagnosis, treatment and follow up were collected.</p><p><strong>Results: </strong>81 patients received at least 1 cycle and were evaluable. The most common oral cavity subsite involved was the buccal mucosa (46%) with stage III (49%) and IVA (51%) equally distributed. 13 (16%) patients had developed grade I toxicities to OMCT. Among 81, 10 (12%) had partial response, and 57 (71%) had stable disease. 14 patients (17%) had disease progression.</p><p><strong>Conclusions: </strong>Oral metronomic chemotherapy in the form of Methotrexate, Capecitabine and Cyclophosphamide is an effective, safe and feasible option to bridge the waiting list period for surgery in locally advanced operable oral cavity squamous cell carcinoma.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13193-026-02596-6.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"841-846"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extra-Pleural Solitary Fibrous Tumors: Clinicopathological Insights and Treatment Outcomes.","authors":"Anand Raja, Hemant Makineni, Ashik Bary, Shalini Shree Krishnamurthy, Shirley Sundersingh, Vivaan Dutt, Chandra Kumar Krishnan","doi":"10.1007/s13193-026-02579-7","DOIUrl":"https://doi.org/10.1007/s13193-026-02579-7","url":null,"abstract":"<p><strong>Introduction: </strong>Solitary fibrous tumors (SFTs) were initially perceived as benign, pleural-based neoplasms but have since been recognized for their potential for local recurrence and distant metastasis, occurring across various anatomical sites. This manuscript delves into the clinicopathological characteristics, treatment outcomes, and follow-up data of patients with SFTs treated at our institution.</p><p><strong>Material and methods: </strong>A retrospective review was conducted on patient charts diagnosed with and treated for extra-pleural SFT at our institute between 2006 and 2017. Data encompassing clinical presentations, diagnostic imaging, therapeutic interventions, histopathological findings, and follow-up details were extracted from electronic case records.</p><p><strong>Results: </strong>Eight patients (four males, four females) with SFT were included. Tumor sizes ranged from 2 cm to 17 cm, with a mean of 9.6 cm. Locations varied, with tumors found in soft tissues and bones. Surgical resection was performed on all patients, with varying outcomes. Five patients remained disease-free during follow-up, while others experienced relapse and metastasis.</p><p><strong>Conclusion: </strong>Historically considered benign, SFTs exhibit variable clinical courses, with local recurrence and distant metastasis reported in a subset of cases. The advent of IHC has improved diagnostic accuracy, revealing characteristic markers such as CD34 and STAT6 positivity. Predicting malignancy remains challenging, necessitating comprehensive histopathological assessment. Surgical resection remains the primary treatment for SFTs, although the roles of adjuvant therapies such as chemotherapy and radiation therapy remain uncertain. The unpredictable nature of SFTs underscores the importance of prolonged follow-up and further research into their molecular biology to develop more effective treatment strategies.</p>","PeriodicalId":46707,"journal":{"name":"Indian Journal of Surgical Oncology","volume":"17 4","pages":"794-799"},"PeriodicalIF":0.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13096460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}